Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Iohexol is a nonionic iodinated radiographic contrast agent. The current Omnipaque label includes intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures in adults and pediatric patients. Injection concentrations range from 140 mg to 350 mg of iodine per mL.
read more about iohexol ...The iodine atoms in iohexol absorb x-rays. Areas containing iohexol attenuate x-rays more strongly than surrounding tissues, which increases contrast on radiographic and computed tomography images. Distribution depends on the route and imaging procedure.
Iohexol is used in adults and pediatric patients for procedure-specific radiographic and computed tomography imaging. Current labeling includes myelography, angiography, urography, computed tomography, gastrointestinal imaging, arthrography, selected biliary and pancreatic imaging, hysterosalpingography, and voiding cystourethrography.
Iohexol concentration and volume depend on the imaging procedure, route, age, body weight, patient condition, and imaging equipment. Current Omnipaque injection strengths contain 140, 180, 240, 300, or 350 mg of iodine per mL. Intrathecal procedures use only the concentrations and presentations specified in current labeling.
Omnipaque carries a boxed warning for severe or fatal reactions when the wrong iodine concentration is administered intrathecally. The 140 mg and 350 mg iodine per mL strengths are not used for intrathecal procedures. Other serious concerns include hypersensitivity reactions, acute kidney injury, cardiovascular reactions, thyroid dysfunction, seizures, and contrast extravasation.
Iohexol is an iodinated contrast agent used for several radiographic and computed tomography imaging procedures.
No. Concentration and volume are selected according to the imaging procedure, route, age, body weight, and patient condition.
The 140 mg and 350 mg iodine per mL strengths are not used for intrathecal procedures.
Yes. Acute kidney injury, including renal failure, can occur after parenteral administration.
ACR Manual on Contrast Media. https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Contrast-Manual. Date Accessed October 5, 2026.
Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/30998567/. Date Accessed October 5, 2026.
Iohexol. https://pubchem.ncbi.nlm.nih.gov/compound/Iohexol. Date Accessed October 5, 2026.
OMNIPAQUE (Iohexol) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=professional&setid=eee15ebe-d349-4497-acef-6abe7a8247fb. Date Accessed October 5, 2026.
Omnipaque. https://www.gehealthcare.com/en-us/products/contrast-media/omnipaque. Date Accessed October 5, 2026.